|Mr. Ian D. Page||CEO, MD & Exec. Director||1.25M||N/A||1961|
|Mr. Paul Nicholas Sandland MAAT, FCCA||CFO & Exec. Director||704k||N/A||1979|
|Dr. Anthony Gerard Griffin||MD of Dechra Veterinary Products for Europe & Exec. Director||643k||N/A||1963|
|Ms. Katy Clough||Group HR Director||N/A||N/A||N/A|
|Mr. Mike Eldred||Pres of North America||N/A||N/A||1970|
|Ms. Melanie Hall||Company Sec.||N/A||N/A||N/A|
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Dechra Pharmaceuticals PLC’s ISS Governance QualityScore as of September 26, 2021 is 4. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 1; Compensation: 2.